Breakthrough invasive fungal diseases during echinocandin treatment in high-risk hospitalized hematologic patients

Annals of Hematology

Volumn 93, Issue 3, 2014, Pages 493-498

  Chan, Thomas S Y ^a   Gill, Harinder ^a   Hwang, Yu Yan ^a   Sim, Joycelyn ^a   Tse, Alan C T ^a   Loong, Florence ^a   Khong, Pek Lan ^a   Tse, Eric ^a   Leung, Anskar Y H ^a   Chim, Chor Sang ^a   Lie, Albert K W ^a   Kwong, Yok Lam ^a  

^a QUEEN MARY HOSPITAL   (Hong Kong)

Author keywords

Breakthrough invasive fungal infections; Echinocandin

Indexed keywords

ADENINE NUCLEOTIDES; ADULT; ANTIBIOTIC PROPHYLAXIS; ANTIFUNGAL AGENTS; ANTIMETABOLITES, ANTINEOPLASTIC; ARABINONUCLEOSIDES; CANDIDA; CANDIDIASIS, INVASIVE; CHINA; COHORT STUDIES; CROSS INFECTION; ECHINOCANDINS; FUSARIOSIS; FUSARIUM; HEMATOLOGIC DISEASES; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOCOMPROMISED HOST; LIPOPEPTIDES; LUNG DISEASES, FUNGAL; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 84894305474     PISSN: 09395555     EISSN: 14320584     Source Type: Journal    
DOI: 10.1007/s00277-013-1882-2     Document Type: Article

References (11)

1. Chen SC, Slavin MA, Sorrell TC (2011) Echinocandin antifungal drugs in fungal infections: a comparison. Drugs 71:11-41
2. Sun HY, Singh N (2010) Characterisation of breakthrough invasive mycoses in echinocandin recipients: an evidence-based review. Int J Antimicrob Agents 35:211-8
3. De Pauw B, Walsh TJ, Donnelly JP et al (2008) European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group; National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 46:1813-21
4. Freifeld AG, Bow EJ, Sepkowitz KA, Boeckh MJ et al (2011) Infectious Diseases Society of America. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america. Clin Infect Dis 52:e56-93
5. Tse E, Leung AY, Sim J et al (2011) Clofarabine and high-dose cytosine arabinoside in the treatment of refractory or relapsed acute myeloid leukaemia. Ann Hematol 90:1277-81
6. Ortega M, Marco F, Soriano A et al (2011) Candida species bloodstream infection: epidemiology and outcome in a single institution from 1991 to 2008. J Hosp Infect 77:157-61
7. Pfaller M, Boyken L, Hollis R et al (2011) Use of epidemiological cutoff values to examine 9-year trends in susceptibility of Candida species to anidulafungin, caspofungin, and micafungin. J Clin Microbiol 49:624-9
8. Pfaller MA (2012) Antifungal drug resistance: mechanisms, epidemiology, and consequences for treatment. Am J Med 125(1 Suppl):S3-13
9. Garcia-Effron G, Katiyar SK, Park S, Edlind TD, Perlin DS (2008) A naturally occurring proline-to-alanine amino acid change in Fks1p in Candida parapsilosis, Candida orthopsilosis, and Candida metapsilosis accounts for reduced echinocandin susceptibility. Antimicrob Agents Chemother 52:2305-12
10. Pang KA, Godet C, Fekkar A et al (2012) Breakthrough invasive mould infections in patients treated with caspofungin. J Infect 64:424-9
11. Chan TS, Hwang YY, Gill H et al (2013) Antifungal drug usage in haematologic patients during a 4-year period in an Asian university teaching hospital. Intern Med J 43(5):541-6